Table 3

Treatment Intensification Rates, Baseline Risk Factor Levels, Declines and Adjusted Mean Differences During Follow-up - Processed vs. Not Processed Patients, Intervention Centers Only, by Priority Level
Processed Not Processed
Priority Percent Processed Intensified within 3 mos (%) Baseline Mean Risk Factor Level Unadjusted Decline Intensified within 3 mos (%) Baseline Mean Risk Factor Level Unadjusted Decline Adjusted Difference (Processed – not Processed) During Follow-up (95% CI)
1: SBP ≥ 140 mmHg 45 40.5 153.4 13.1 28.8 153.0 14.1 1.01
(0.30, 1.75)
2: LDL-c ≥ 130 mg/dL 46 36.3 152.8 25.9 21.0 153.4 24.0 -0.6
(-3.4, 2.2)
3: A1c ≥ 9% 47 32.6 10.3 1.0 26.7 10.2 1.0 -0.03
(-0.19, 0.14)
4:SBP 130-139£ 29 27.4 138.9 5.6 21.1 138.4 6.2 1.06
(0.44, 1.69)
5: LDL-c 100-129 mg/dL 30 29.2 111.2 10.4 16.8 111.4 10.0 0.63
(-0.95, 2.22)
6. A1c 7-8.9% 28 28.9 7.6 -0.1 25.3 7.5 -0.1 -0.03
(-0.09, 0.04)

Processed: Record review and outreach initiated by staff in response to identification of eligibility for treatment intensification.

Based on the last value recorded before follow-up begins; i.e., the value that qualified patient for treatment intensification.

Based on the first value recorded after 3 months follow-up; if no values recorded between 3 and 12 months follow-up, the latest value recorded during first 3 months follow-up was used.

From repeated measures models using all available values during follow-up,with adjustment for age, gender, race-ethnicity, baseline risk factor value, number of medications for the risk factor at baseline, and days of follow-up at time of each measurement. Negative value indicates that the adjusted values were lower in the processed group during follow-up.

£ Only patients with diabetes mellitus and/or chronic kidney disease were eligible for the target of SBP <130 mmHg.

Selby et al.

Selby et al. BMC Health Services Research 2012 12:183   doi:10.1186/1472-6963-12-183

Open Data